Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VK2735-101 subcutaneous parts A and B

49 evidence topics · 8 sources

Objective
Location and study date
Single centre in Adelaide, Australia, in the ISRCTN record
FieldRegistry value
Countries of recruitment“Australia”
Study participating centre“Cmax Clinical Research Pty Ltd”
Date of first enrolment“01/12/2021”
Date of final enrolment“01/06/2023”
Planned study period“December 2021 to December 2022”
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Study start (actual)“2021-12-14”
Primary completion (actual)“2024-11-04”
Study completion (actual)“2024-12-03”
Site“Viking Clinical Site”
Site city“Adelaide”
Study design
Eligibility criteria
Treatment
Subcutaneous formulation: weekly dose levels in the multiple ascending dose cohorts
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Enrollment (actual)“92”
Participants analyzed in the multiple ascending dose cohorts
GroupParticipants analyzed for body weight
Placebo“(n=10)”
VK2735 0.5 mg“(n=6)”
VK2735 1.5 mg“(n=6)”
VK2735 1.5/3/5/5 mg“(n=7)”
VK2735 3/5/5/7.5 mg“(n=6)”
VK2735 5/5/7.5/10 mg“(n=6)”
Participants analyzed for liver fat
GroupParticipants analyzedSubset with nonalcoholic fatty liver disease
Placebo“(n=8)”“n=3”
VK2735 0.5 mg“(n=6)”“n=0”
VK2735 1.5 mg“(n=6)”“n=4”
VK2735 1.5/3/5/5 mg“(n=6)”“n=4”
VK2735 3/5/5/7.5 mg“(n=6)”“n=4”
VK2735 5/5/7.5/10 mg“(n=4)”“n=1”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Mean baseline body weight in the multiple ascending dose cohorts
GroupMean baseline body weight (kg)
Placebo (n=10)“121.1”
VK2735 0.5 mg (n=6)“101.2”
VK2735 1.5 mg (n=6)“114.8”
VK2735 1.5/3/5/5 mg (n=7)“115.3”
VK2735 3/5/5/7.5 mg (n=6)“116.3”
VK2735 5/5/7.5/10 mg (n=6)“95.9”
Mean baseline liver fat content in the multiple ascending dose cohorts
GroupMean baseline liver fat content (%)
Placebo (n=8)“6.59”
VK2735 0.5 mg (n=6)“2.58”
VK2735 1.5 mg (n=6)“7.84”
VK2735 1.5/3/5/5 mg (n=6)“8.14”
VK2735 3/5/5/7.5 mg (n=6)“11.1”
VK2735 5/5/7.5/10 mg (n=4)“3.96”
Efficacy results
Change in body weight by multiple ascending dose cohort at day 28
MeasurePlacebo (n=10)0.5 mg (n=6)1.5 mg (n=6)1.5/3/5/5 mg (n=7)3/5/5/7.5 mg (n=6)5/5/7.5/10 mg (n=6)
Mean change from baseline body weight“-2.2 kg”“-2.6 kg”“-4.1 kg”“-4.5 kg”“-8.2 kg”“-7.6 kg”
Mean percent change from baseline“-1.8 %”“-2.5 %”“-3.7 %”“-4.1 %”“-7.4 %”“-7.8 %”
Placebo-adjusted mean change from baseline“-”“-0.7 %”“-1.9 %”“-2.3 %”“-5.6 %”“-6.0 %”
p-value vs. placebo“-”“0.64”“0.17”“0.09”“0.0003”“0.0002”
Change in liver fat content by multiple ascending dose cohort
MeasurePlacebo0.5 mg1.5 mg1.5/3/5/5 mg3/5/5/7.5 mg5/5/7.5/10 mg
Mean percent change from baseline, all participants“-0.7”“3.9”“-24.2”“-24.0”“-47.2”“-8.4”
p-value vs. placebo, all participants“-”“0.74”“0.09”“0.10”“0.002”“0.62”
Mean percent change from baseline, nonalcoholic fatty liver disease subset“8.8”“-”“-33.8”“-32.5”“-49.7”“-10.7”
p-value vs. placebo, nonalcoholic fatty liver disease subset“-”“-”“0.03”“0.03”“0.006”“-”
Change in plasma lipids by multiple ascending dose cohort
MeasurePlacebo (n=9)0.5 mg (n=6)1.5 mg (n=6)1.5/3/5/5 mg (n=6)3/5/5/7.5 mg (n=6)5/5/7.5/10 mg (n=4)
Mean change in apolipoprotein B from baseline (%)“1.8”“3.3”“-1.8”“-12.9”“-12.5*”“-20.5”
Mean change in LDL-C from baseline (%)“-9.5”“1.4”“-10.6”“-13.7”“-20.3*”“-23.0”
Mean change in total cholesterol from baseline (%)“-5.1”“-1.7”“-10.8”“-14.9*”“-17.4*”“-21.0”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Commonly reported adverse events by multiple ascending dose cohort
Study limitations
Summary: study limitations

VK2735-101 Parts A and B were the first administration of VK2735 to humans, conducted at a single centre in Adelaide, Australia, in healthy adults (Part A) and otherwise healthy adults with a body mass index of at least 30 kg/m2 (Part B). The registered primary endpoint was the incidence of treatment-emergent adverse events, and body weight, liver fat, and lipids were exploratory pharmacodynamic measures. The multiple ascending dose part dosed participants once weekly for 4 weeks, with 6 or 7 participants in each VK2735 cohort and 10 receiving placebo, and the highest weekly dose (10 mg) is lower than the doses later carried into phase 2 and phase 3. The liver fat subgroup with nonalcoholic fatty liver disease contained 0 to 4 participants per cohort. Single-dose results by dose level, participant disposition, and baseline characteristics other than body weight and liver fat were not reported. The ISRCTN record named nonalcoholic steatohepatitis as the condition VK2735 was being developed for and a target sample size of 88; the ClinicalTrials.gov record reports an actual enrollment of 92 for Parts A, B, and C combined, whereas the oral first-in-human poster reports that 92 participants were randomized in the oral part alone. The two documents also differ on the time to maximum concentration (approximately 75 to 90 hours in the results release and about 72 hours in the corporate presentation). Results are available only in press releases, a corporate presentation, and a congress abstract, with no peer-reviewed full publication and no results posted to either registry.